Pulse ·

Circadian depression: a body-clock subtype affecting mostly women

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

University of Sydney researchers identified circadian depression — a subtype in about 23% of people with persistent depression. Around 80% of cases are in women. It tends to begin earlier (around age 18), associates with more frequent suicidal ideation, and appears less responsive to standard antidepressants.

This subtype responds better to melatonin, agomelatine, and light therapy — not routine first-line options in Australian general practice.

International replication is still needed. But if standard treatment hasn't moved the needle, the circadian angle — sleep timing, light exposure, melatonin — is worth raising with your GP.

If you have been told your depression is “treatment-resistant” — or if you have tried two or three antidepressants and found them either ineffective or barely worth the side-effect trade — there is new Australian research published this week that may be directly relevant to you.

The finding, from the University of Sydney’s Brain and Mind Centre and published in the British Journal of Psychiatry, describes what the researchers are calling circadian depression — a subtype of depression linked to the body’s 24-hour internal clock. They found it in roughly one in four Australians with severe, recurrent, or persistent depression. And here is the part worth sitting with: around 80% of those with this subtype are female.

That is not a minor footnote. It is a signal.

What the study actually found

The researchers analysed data from more than 11,000 Australians enrolled in the Australian Genetics of Depression Study — a substantial, nationally representative dataset. They were specifically looking for patterns within the depression diagnosis that standard clinical criteria don’t carve out.

Circadian depression, as they’ve defined it, clusters around disruption to the body clock: irregular sleep-wake patterns, mood that shifts predictably across the day, and a biological signature that includes elevated genetic risk for inflammatory, cardiovascular, and neurodevelopmental conditions — including ADHD.

A few features stand out clinically:

  • It starts earlier. Average onset around age 18, compared to 23 for non-circadian depression.
  • It associates with more frequent suicidal ideation. This doesn’t mean it’s more dangerous in every case — it means the clinical picture is heavier and warrants more careful monitoring.
  • It looks less responsive to standard first-line antidepressants — the SSRIs and SNRIs that are typically the first thing prescribed in Australian general practice.

The proposed treatment profile is different: melatonin, agomelatine (a melatonin-receptor antidepressant registered in Australia), and structured light therapy all appear to offer better response in this subtype than standard antidepressants. These are not novel compounds. They are not fringe treatments. But they are not routine first-line options in a standard 15-minute GP consultation, and that gap matters enormously for the women sitting in the gap.

Both-and: what to hold simultaneously

Here is what it would be too easy to conclude: “My depression is circadian. My current antidepressant is the wrong one.”

That would be moving too fast.

The researchers themselves are careful about this. The paper is a first identification — not a clinical diagnostic tool yet. International replication is needed before this becomes a formal diagnostic category that changes prescribing guidelines. The researchers specifically call for digital phenotyping with wearables and apps as a next step, to capture the circadian signature more precisely. There is no validated clinical test you can walk in and ask for today.

Hold that reality.

And hold this one alongside it: the fact that circadian mechanisms have been historically underweighted in depression research is not accidental. Depression research has, for decades, been conducted predominantly in male populations, with diagnostic tools that don’t consistently capture the experience of female patients. An 80% female prevalence in this subtype does not come from nowhere — it reflects something that has been sitting in plain sight for years, invisible largely because the research lens wasn’t pointed at it.

The system didn’t fail you on purpose. It failed you structurally. Those are different problems, and naming them correctly matters for how you navigate what comes next.

2 cents: what this means for your terrain this week

If you are managing depression that hasn’t fully responded to antidepressant treatment — and particularly if any of these features sound familiar:

  • Your mood has a daily rhythm (worse at a predictable time of day or night)
  • Sleep disruption feels like a core feature of your illness, not just a symptom
  • You’ve had more than two antidepressants that “didn’t really work” or stopped working
  • Your depression first appeared in your teens or early twenties

…then the circadian angle is worth raising explicitly in your next GP appointment. Not as a self-diagnosis. As a question: “I’ve been reading about circadian depression — is my sleep-wake pattern something worth investigating as part of my treatment picture?”

Light therapy (a properly calibrated 10,000-lux light box, used for 20–30 minutes in the morning) is low-risk enough to discuss as a first step even before any prescribing changes. Melatonin in low doses (0.5–1mg, taken 6–7 hours before bed to shift the phase) is another conversation worth having. Neither of these will harm a standard SSRI if you’re already on one — but they deserve a proper shared-decision discussion with your prescriber, not a self-directed trial.

Agomelatine is a more involved conversation: it’s a registered antidepressant in Australia with a different mechanism (melatonin receptor agonist plus 5-HT₂C antagonism), and it requires liver function monitoring. It’s not something to reach for outside a proper GP consultation. But it exists, it’s on the PBS, and it may be more appropriate than a third or fourth SSRI trial for some patients. Knowing its name is a useful thing to bring to the table.

This is early-stage science that may reshape how we classify and treat depression in women. It is not yet a clinical protocol. But it is a permission slip to ask better questions, and sometimes that is exactly what moves the conversation forward.

Verdict: yes — this is worth knowing about.

If you need to talk to someone now: Lifeline 13 11 14 (24/7, call or text 0477 13 11 14) · Beyond Blue 1300 22 4636 · Suicide Call Back Service 1300 659 467 · 13YARN (First Nations) 13 92 76 · Emergency 000

Sources cited

  1. Researchers identify new depression sub-type — newsGP, 21 Oct 2026
  2. Circadian depression paper — British Journal of Psychiatry (via Scimex)
  3. Australian Genetics of Depression Study — QIMR Berghofer

Frequently asked questions

  • What is circadian depression?

    Circadian depression is a proposed subtype of depression linked to disruption in the body's 24-hour clock. A 2026 Australian study found it affects about 23% of people with severe or persistent depression, with 80% of cases in women. It may respond better to light therapy and melatonin-based treatments than to standard antidepressants.

  • How is circadian depression treated differently?

    Standard antidepressants appear less effective for this subtype. The University of Sydney research points to better responses from melatonin supplementation, agomelatine (a melatonin-receptor antidepressant), and structured light therapy. These are not standard first-line options in Australian general practice — raise this with your GP if you've had a limited response to usual treatment.